The effect of CIBA 32,644-Ba in the treatment of 1,059 cases of vesical and intestinal schistosomiasis

Publisher Website
Google Scholar
Abstract
A total of 1,059 patients (987 with vesical schistosomiasis and 72 with intestinal schistosomlasls) were treated with CIBA 32,644-Ba. Several therapeutic schedules were used in a preliminary trial on 300 patients infected with Schistosoma haematobium and on 30 infected with Schistosoma mansoni. In a subsequent trial the dosage scheme adopted for the mass treatment of 687 patients infected with S. haematobium and of 42 infected with S. mansoni was a single daily dose of 25-30 mg/kg given on 4 consecutive days. The over-all "cure" rate in 1,007 patients followed up for a period of 4 months was 84.2%. This rate is significantly higher than we had previously obtained under similar conditions with other antischistosomal drugs. The compound was generally well tolerated; side-effects were mild, and it was not necessary to interrupt treatment in any of the patients. The results of the trial indicate that CIBA 32,644-Ba is highly effective in the treatment of S. haematobium and S. mansoni infections. In view of its great activity and of the fact that it can be administered orally, it is considered a valuable drug for the mass treatment of schistosomiasis.

This publication has 2 references indexed in Scilit: